1. Novel oral anticoagulants and reversal agents: considerations for clinical development;Sarich;Am. Heart J.,2015
2. European Medicines Agency 2015 Summary of the European Public Assessment Report (EPAR) for Praxbind http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003986/human_med_001938.jsp&mid=WC0b01ac058001d124
3. U. S. Foodand Drug Administration 2016 CDER Breakthrough Therapy Designation Approvals http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/NDAandBLAApprovalReports/UCM481542.pdf
4. DIGOXIN 2015 US Prescribing Information http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021648s008lbl.pdf
5. Praxbind® (Idarucizumab) Injection 2015 F.I.U http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/761025lbl.pdf